Acelrx pharmaceuticals to acquire lowell therapeutics and reports third quarter 2021 financial results

Hayward, calif., nov. 15, 2021 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the execution of a definitive merger agreement to acquire lowell therapeutics, inc. (lowell), a privately held company, and reported its third quarter 2021 financial results.
ACRX Ratings Summary
ACRX Quant Ranking